Introduction
IL-17C is one of the members of the IL-17 cytokine family. In recent years, its role in inflammation and autoimmune diseases has gradually been discovered and thus has attracted attention. IL-17C is associated with various diseases, such as psoriasis, rheumatoid arthritis, osteoarthritis, etc.
The content of IL-17C significantly increases in psoriasis lesions, making IL-17C applicable as an auxiliary diagnostic indicator for psoriasis. IL-17C exacerbates epidermal barrier disruption by promoting abnormal proliferation of keratinocytes and the release of inflammatory factors, and its effect is independent of IL-17A. This characteristic implies that drugs targeting IL-17C may have the ability to provide supplementary treatment for patients with insufficient efficacy of IL-17A inhibitors.
In terms of inflammation, IL-17C can exert a crucial role in inflammation by activating the NF-κB and MAPK signaling pathways, promoting the release of pro-inflammatory factors (IL-6, TNF-α) and chemokines, and enhancing the recruitment of neutrophils. This makes IL-17C play an important role in the basic research of related immune diseases. Meanwhile, research experiments in this field have shown that inhibiting IL-17C can significantly reduce the level of p-NF-κB, thereby inhibiting the activation of inflammatory macrophages. This provides a theoretical basis for the development of new biological agents targeting joint destruction in rheumatoid arthritis, and also indicates that IL-17C has the potential to assist pharmaceutical companies in developing IL-17 series drugs.
IL-17C shares some receptor subunits (IL-17RA/RC) with other members of the IL-17 family, but its cellular origin and downstream signaling characteristics are different from those of other members. This difference can explain its prominent role in certain tissue-specific inflammation and also suggests that combined inhibition of different IL-17 subtypes may produce synergistic therapeutic effects. Based on this idea, the development of bispecific antibodies (targeting IL-17C and other members) or combination therapy (simultaneously inhibiting multiple members) for IL-17-related diseases may enhance therapeutic efficacy. At the same time, the relationship between IL-17C and other IL-17 members makes IL-17C a supplementary marker when there are individual differences in responses to inhibitors targeting other members. This allows for the expression level of IL-17C to be correlated with the disease, which may help establish more precise efficacy prediction models and guide clinical treatment.
IL-17C is currently regarded as an emerging biomarker. It has shown great potential in the diagnosis and treatment of diseases such as psoriasis and arthritis, as well as in the screening of therapeutic targets, prognosis assessment, pathological mechanism research, and drug development. The changes in its concentration are significantly correlated with the progression and therapeutic response of various diseases.
Product Feature
HKIG’s Innovative Product: IL-17C ELISA Kit HS, Facilitating Accurate Detection of IL-17C Index. It has the following features:
High sensitivity: This kit employs a specific antibody sandwich Elisa method. The detection limit for serum samples is as low as 10 pg/mL.
Efficient and Convenient: This kit enables rapid detection within 3 hours. The operation is simple and straightforward, and it can be used immediately upon opening, significantly enhancing the detection efficiency.
Other advantages: This kit has good stability, strong specificity and is economical and cost-effective. The detection cost is low.
Product Information
| Product Name | Catalog No. | Size |
| IL-17C Elisa Kit | 3018 | 96T |
| IL-17C Elisa Kit HS | 3018HS | 96T |
Welcome for inquiry！
